<DOC>
	<DOCNO>NCT03018834</DOCNO>
	<brief_summary>There specific treatment acute myocarditis , especially inflammatory period . Interleukin ( IL ) specifically involved period play role myocardial oedema . ANAKINRA , IL-1β Blocker , new treatment never evaluate myocarditis . The benefit patient could important reduction heart failure ventricular arrhythmia . Hypothesis : ANAKINRA addition standard therapy treatment Acute Myocarditis superior standard therapy base association beta-blockers Angiotensin-Converting-Enzyme inhibitor ( ACE ) .</brief_summary>
	<brief_title>Anakinra Versus Placebo Treatment Acute MyocarditIS</brief_title>
	<detailed_description>It Double Blind Randomized clinical trial Phase IIb superiority , enrol two group : one group treat standard care , define maximum tolerated dosage beta blocker ACE , placebo versus ANAKINRA addition standard care patient treat acute Myocarditis . Patients randomize receive ANAKINRA 100 mg/daily placebo subcutaneously day hospital discharge , maximum 14 day , addition standard care : ACE Beta-blocker 6 month . Randomization 1:1 conduct centrally use electronic Case Report Form ( eCRF ) . As exploratory analysis , second randomization ACE discontinuation patient without left ventricular dysfunction ( LVEF &gt; 50 % ) one month post discharge perform . One group stop treatment one month second group continue ACE 6 month . This second randomization open label .</detailed_description>
	<mesh_term>Myocarditis</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Patients hospitalize Acute myocarditis define : Chest Pain ( modification ECG ) AND Troponin Rise ( *1.5 Normal range ) AND Myocarditis proven MRI first 72h admission Age &gt; 18 &lt; 65 year old Accepting effective contraception treatment duration ( men woman childbearing potential ) Signed informed consent Normal Coronary angiography coronary CT Scan ( make previous year acceptable ) ( normal define stenosis &lt; 50 % ) Active coronary disease Clinical Suspicion proven underlie disease : systemic lupus , antiphospholipid antibody , Lyme disease , trypanosomiase disease , myositis , sign sarcoidosis , giant cell myocarditis , chronic inflammatory disease , tuberculosis , HIV , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection Latex allergy Pregnancy , breastfeed Contraindication ANAKINRA ( know hypersensitivity active substance excipients , neutropenia &lt; 1,5.109/L ) Renal failure , Creatine Clearance ( CrCl ) &lt; 30 ml/min ( MDRD ) Asthma Malignancy comorbidity limit survival condition predict inability complete study History malignancy Non Steroidian Anti Inflammatory drug within past 14 day Anti Tumor Necrosis Factor ( TNF ) within past 14 day No affiliation French Health Care System `` sécurité sociale '' Hepatic impairment = ChildPugh Class C Mechanical ventilation Circulatory assistance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Acute Myocarditis</keyword>
	<keyword>ANAKINRA</keyword>
</DOC>